Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum strains 299 and 299v (Children's Oncology Group)
- Development stage
- Unknown
- Lead developer
- Children's Oncology Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus plantarum strains 299 and 299v** is an orally administered live probiotic preparation evaluated by the Children's Oncology Group as an investigational microbiome therapy for prevention of gastrointestinal acute graft-versus-host disease after alternative-donor allogeneic hematopoietic cell transplantation in children and young adults. The preparation contains two genetically similar strains, *Lactobacillus plantarum* 299v (DSM 9843) and *Lactobacillus plantarum* 299 (DSM 6595), now classified as *Lactiplantibacillus plantarum*. It is intended to support intestinal mucosal integrity and beneficial microbiome composition, potentially reducing gastrointestinal inflammation and susceptibility to acute graft-versus-host disease. In the randomized Phase 3 ACCL1633 trial, dosing began with conditioning and continued through day 56 after transplantation; the product was well tolerated without reported *Lactobacillus* bacteremia but did not significantly prevent gastrointestinal acute graft-versus-host disease versus placebo.
- Other names
- Lactiplantibacillus plantarum strains 299 and 299vLBPLBP 299vLBP299vLBP-299v
Beyond the preview
Go deeper on lactobacillus plantarum strains 299 and 299v (Children's Oncology Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum strains 299 and 299v (Children's Oncology Group).